Nkarta Inc (NKTX) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Nkarta Inc stock (NKTX) is currently trading at $2.05. Nkarta Inc PS ratio (Price-to-Sales) is 1000000.00. Analyst consensus price target for NKTX is $14.00. WallStSmart rates NKTX as Sell.
- NKTX PE ratio analysis and historical PE chart
- NKTX PS ratio (Price-to-Sales) history and trend
- NKTX intrinsic value — DCF, Graham Number, EPV models
- NKTX stock price prediction 2025 2026 2027 2028 2029 2030
- NKTX fair value vs current price
- NKTX insider transactions and insider buying
- Is NKTX undervalued or overvalued?
- Nkarta Inc financial analysis — revenue, earnings, cash flow
- NKTX Piotroski F-Score and Altman Z-Score
- NKTX analyst price target and Smart Rating
Nkarta Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Nkarta Inc (NKTX) · 5 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book, institutional own.. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Nkarta Inc (NKTX) Key Strengths (2)
Trading below book value, meaning the market prices it less than net assets
78.38% of shares held by major funds and institutions
Supporting Valuation Data
Nkarta Inc (NKTX) Areas to Watch (3)
Company is destroying shareholder value
Very expensive at 1000000.0x annual revenue
Micro-cap company with very limited liquidity and high volatility
Supporting Valuation Data
Nkarta Inc (NKTX) Detailed Analysis Report
Overall Assessment
This company scores 25/100 in our Smart Analysis, earning a F grade. Out of 5 metrics analyzed, 2 register as strengths (avg 10.0/10) while 3 fall into concern territory (avg 1.7/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book, Institutional Own.. Valuation metrics including Price/Book (0.46) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Price/Sales, Market Cap. Some valuation metrics including Price/Sales (1000000.00) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -26.70%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -26.70% needing improvement to support the investment thesis. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Price/Sales are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
NKTX Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
NKTX's Price-to-Sales ratio of 1000000.00x sits near its historical average of 1000000x (0th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 0% below its historical high of 1000000x set in Mar 2026, and 0% above its historical low of 1000000x in Mar 2026.
WallStSmart Analysis Synopsis
Data-driven financial summary for Nkarta Inc (NKTX) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Nkarta Inc operates as a stable business with moderate growth and solid fundamentals. Revenue reached 385 with 0% growth year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Spending 5246234% of revenue (20M) on R&D, reinforcing its commitment to innovation and future growth.
Free cash flow is -19M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Nkarta Inc.
Bottom Line
Nkarta Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Nkarta Inc(NKTX)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and markets cell therapies for the treatment of cancer. The company is headquartered in South San Francisco, California.